Not received any observation from USFDA audit: Claris Lifesciences

New Delhi: Claris Lifesciences underwent an audit by the USFDA for pharmacovigilance in the last week of May and has not received any observation.
“Claris Lifesciences along with its wholly-owned subsidiary Claris Injectables Ltd announced today that it underwent a successful USFDA Pharmacovigilance (PV) audit from May 29-31 with no observation (i483s),” the company said in a BSE filing.
The company shares were trading up by 4.34 per cent at Rs. 341.25 on the BSE.
ClarisClaris Injectables LtdClaris Lifesciencesindian pharma newsno observationpharma newspharma news indiapharmacovigilanceUSFDA
Source : PTINext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd